Earlier this week, the FDA reached an agreement with Abbott ( ABT ) on steps necessary to resume production at its Sturgis, Michigan infant formula plant. Abbott estimates production at the plant could resume two weeks after FDA approval and take up to eight weeks for the product to hit store shelves. FDA Commissioner Dr. Robert Califf gave a similar timeframe earlier this week, estimating supply will improve "in the next couple of months."